GSK shares drop after the UK drugmaker reports weaker vaccine sales and warns costs and restructuring charges will continue to weigh on earnings. The Guardian reports investors react negatively despite reporting results that are better than expected, highlighting a weaker overall outlook.
Across outlets, attention focuses on falling performance in GSK’s vaccines business, including waning demand for products such as shingles and RSV jabs, and pressure from markets like China. The Guardian also notes restructuring charges and declining pre-tax profit, while the Independent provides a specific quarterly figure showing vaccine sales down 2% to £2.6 billion in the three months to September 30.
The Financial Times adds detail by linking the sales weakness to falling Chinese demand for the shingles vaccine. Belfast Telegraph similarly emphasises that vaccine sales decline takes shine off earnings, though its provided summary contains fewer additional specifics.
Overall, the coverage agrees that vaccine weakness is a key driver of investor concern, with different outlets varying in the amount of financial detail and the specific market and product dynamics they foreground.
